Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network
Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histopathological slides, has been shown to be a very powerful...
Saved in:
| Published in | Journal of hematopathology Vol. 2; no. 2; pp. 103 - 111 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer-Verlag
01.07.2009
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1868-9256 1865-5785 |
| DOI | 10.1007/s12308-009-0036-x |
Cover
| Abstract | Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histopathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2 × 500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network
.
Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2 × 100 cells) showed high interobserver agreement (CCC = 0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given. |
|---|---|
| AbstractList | Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histopathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2 × 500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network. Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2 × 100 cells) showed high interobserver agreement (CCC = 0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given. Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive lymphoma cells on histopathological slides, has been shown to be a very powerful prognostic biomarker. The pathology panel of the European MCL Network evaluated methods to assess the Ki-67 index including stringent counting, digital image analysis, and estimation by eyeballing. Counting of 2 × 500 lymphoma cells is the gold standard to assess the Ki-67 index since this value has been shown to predict survival in prospective randomized trials of the European MCL Network . Estimation by eyeballing and digital image analysis showed a poor concordance with the gold standard (concordance correlation coefficients [CCC] between 0.29 and 0.61 for eyeballing and CCC of 0.24 and 0.37 for two methods of digital image analysis, respectively). Counting a reduced number of lymphoma cells (2 × 100 cells) showed high interobserver agreement (CCC = 0.74). Pitfalls of the Ki-67 index are discussed and guidelines and recommendations for assessing the Ki-67 index in MCL are given. |
| Author | Loddenkemper, Christoph Stein, Harald Dreyling, Martin Barth, Thomas E. F. Hiddemann, Wolfgang Unterhalt, Michael van Krieken, Johan H. Cabeçadas, José Rosenwald, Andreas van der Laak, Jeroen Möller, Peter Bernd, Heinz Wolfram Wacker, Hans Heinrich Ralfkiaer, Elisabeth Hansmann, Martin Leo Müller-Hermelink, Konrad Klapper, Wolfram Kodet, Roman Hoster, Eva Berger, Françoise Ott, German Krivolapov, Yuri A. Oschlies, Ilske Cogliatti, Sergio Campo, Elias Kluin, Philip M. Rymkiewicz, Grzegorz Determann, Olaf Pileri, Stefano |
| Author_xml | – sequence: 1 givenname: Wolfram surname: Klapper fullname: Klapper, Wolfram email: wklapper@path.uni-kiel.de organization: Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel – sequence: 2 givenname: Eva surname: Hoster fullname: Hoster, Eva organization: Department of Internal Medicine III, University of Munich – sequence: 3 givenname: Olaf surname: Determann fullname: Determann, Olaf organization: Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel – sequence: 4 givenname: Ilske surname: Oschlies fullname: Oschlies, Ilske organization: Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel – sequence: 5 givenname: Jeroen surname: van der Laak fullname: van der Laak, Jeroen organization: Department of Pathology, Radboud University Nijmegen Medical Centre – sequence: 6 givenname: Françoise surname: Berger fullname: Berger, Françoise organization: Service d’Anatomie Pathologique, Centre Hospitalier et Faculté Lyon Sud – sequence: 7 givenname: Heinz Wolfram surname: Bernd fullname: Bernd, Heinz Wolfram organization: Department of Pathology, University Hospital Schleswig-Holstein, Campus Lübeck – sequence: 8 givenname: José surname: Cabeçadas fullname: Cabeçadas, José organization: Serviço de Anatomia Patológica, IPOLFG – sequence: 9 givenname: Elias surname: Campo fullname: Campo, Elias organization: Hospital Clinic, Unitat d’Hematopatologia – sequence: 10 givenname: Sergio surname: Cogliatti fullname: Cogliatti, Sergio organization: Institut für Pathologie – sequence: 11 givenname: Martin Leo surname: Hansmann fullname: Hansmann, Martin Leo organization: Department of Pathology, University of Frankfurt – sequence: 12 givenname: Philip M. surname: Kluin fullname: Kluin, Philip M. organization: Department of Pathology and Laboratory Medicine, Groningen University Hospital – sequence: 13 givenname: Roman surname: Kodet fullname: Kodet, Roman organization: Department of Pathology and Molecular Medicine, 2nd Medical School and Faculty Hospital, Charles University – sequence: 14 givenname: Yuri A. surname: Krivolapov fullname: Krivolapov, Yuri A. organization: Department of Imunohistochemistry, Leningrad Regional Bureau of Pathology – sequence: 15 givenname: Christoph surname: Loddenkemper fullname: Loddenkemper, Christoph organization: Department of Pathology, University Hospital Charité Campus Benjamin Franklin – sequence: 16 givenname: Harald surname: Stein fullname: Stein, Harald organization: Department of Pathology, University Hospital Charité Campus Benjamin Franklin – sequence: 17 givenname: Peter surname: Möller fullname: Möller, Peter organization: Department of Pathology, University of Ulm – sequence: 18 givenname: Thomas E. F. surname: Barth fullname: Barth, Thomas E. F. organization: Department of Pathology, University of Ulm – sequence: 19 givenname: Konrad surname: Müller-Hermelink fullname: Müller-Hermelink, Konrad organization: Department of Pathology, University of Würzburg – sequence: 20 givenname: Andreas surname: Rosenwald fullname: Rosenwald, Andreas organization: Department of Pathology, University of Würzburg – sequence: 21 givenname: German surname: Ott fullname: Ott, German organization: Department of Clinical Pathology, Robert-Bosch-Krankenhaus – sequence: 22 givenname: Stefano surname: Pileri fullname: Pileri, Stefano organization: Institute of Haematology and Clinical Oncology “L. and A. Seragnoli”, Unit of Haematopathology, University of Bologna – sequence: 23 givenname: Elisabeth surname: Ralfkiaer fullname: Ralfkiaer, Elisabeth organization: Rigshospitalet, University of Copenhagen – sequence: 24 givenname: Grzegorz surname: Rymkiewicz fullname: Rymkiewicz, Grzegorz organization: Department of Pathology, Maria Sklodowska-Curie Memorial Cancer Center – sequence: 25 givenname: Johan H. surname: van Krieken fullname: van Krieken, Johan H. organization: Department of Pathology, Radboud University Nijmegen Medical Centre – sequence: 26 givenname: Hans Heinrich surname: Wacker fullname: Wacker, Hans Heinrich organization: Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel – sequence: 27 givenname: Michael surname: Unterhalt fullname: Unterhalt, Michael organization: Department of Internal Medicine III, University of Munich – sequence: 28 givenname: Wolfgang surname: Hiddemann fullname: Hiddemann, Wolfgang organization: Department of Internal Medicine III, University of Munich – sequence: 29 givenname: Martin surname: Dreyling fullname: Dreyling, Martin organization: Department of Internal Medicine III, University of Munich |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19669190$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcuOFCEYhYkZ41z0AdwYXqAUiuK2MTGd8RJb3eiaUEBVM0NDBarG7o3xIXxCn0TadibqYhaEEzjfSf7_nIOTmKID4ClGzzFC_EXBLUGiQUjWQ1izewDOsGC0oVzQk99aNLKl7BScl3KFEOs6SR6BUywZk1iiM_DtvW8Yh7pADaecxpjK7A3c6nztMvSxqjgHB40LAYb9dtqkrf75_YdJsbhYlgLHxVsXfHQFpgHOGwcnPW9SSOO-qujC7fPlktPkdIQfVmv40c1fU75-DB4OOhT35M99Ab68vvy8etusP715t3q1bkzXkl1jLROWMiN71HPpEBNkaG1HtOTSSkp6axDRvSGaC4EotaRFTPMOdY6jARtyAV4ec6el3zprXJyzDmrKvk66V0l79e9P9Bs1phvV8pa2AteAZ38H3JG3m6wGfjSYnErJblDGz3r26ZDng8JIHTpTx85U7UwdOlO7SuL_yLvwe5j2yJTqjaPL6iotOdYV3gP9Aqw4rRg |
| CitedBy_id | crossref_primary_10_1016_j_lpm_2019_07_025 crossref_primary_10_1053_j_seminhematol_2011_03_010 crossref_primary_10_1007_s00277_013_1783_4 crossref_primary_10_7243_2055_091X_5_3 crossref_primary_10_1111_his_12009 crossref_primary_10_1002_ajh_26523 crossref_primary_10_1200_JCO_2016_70_7901 crossref_primary_10_1111_ejh_12539 crossref_primary_10_1080_10428194_2023_2216819 crossref_primary_10_1111_his_12092 crossref_primary_10_1111_j_1365_2141_2012_09174_x crossref_primary_10_1007_s12308_014_0199_y crossref_primary_10_1007_s12022_015_9379_2 crossref_primary_10_1200_EDBK_175448 crossref_primary_10_7314_APJCP_2015_16_15_6591 crossref_primary_10_1093_annonc_mds643 crossref_primary_10_1200_JCO_2013_52_2466 crossref_primary_10_1007_s12308_020_00418_4 crossref_primary_10_3816_CLML_2010_n_066 crossref_primary_10_1016_j_critrevonc_2011_05_001 crossref_primary_10_1182_blood_2017_08_737502 crossref_primary_10_1080_10428194_2016_1231404 crossref_primary_10_1002_cncr_30068 crossref_primary_10_3109_10428194_2012_733882 crossref_primary_10_1182_blood_2009_08_236570 crossref_primary_10_1016_j_prp_2018_02_015 crossref_primary_10_1002_cam4_2565 crossref_primary_10_1056_NEJMc1210783 crossref_primary_10_1182_blood_2015_02_628792 crossref_primary_10_1007_s00428_010_0922_8 crossref_primary_10_1186_s13046_017_0652_8 crossref_primary_10_1016_j_humpath_2014_10_001 crossref_primary_10_1016_S1470_2045_15_00438_6 crossref_primary_10_3390_ijms241210207 crossref_primary_10_1007_s12308_010_0069_1 crossref_primary_10_21320_2500_2139_2023_16_2_213_226 crossref_primary_10_1002_prca_201000048 crossref_primary_10_1158_1078_0432_CCR_14_0836 crossref_primary_10_1007_s00277_018_3318_5 crossref_primary_10_1093_annonc_mdu264 crossref_primary_10_1093_annonc_mdv111 crossref_primary_10_3390_medicina60030476 crossref_primary_10_1007_s12308_009_0052_x crossref_primary_10_1007_s00428_014_1632_4 crossref_primary_10_1053_j_seminhematol_2011_03_006 crossref_primary_10_1007_s13277_015_3203_y crossref_primary_10_1111_bjh_19153 crossref_primary_10_1002_ajh_25487 crossref_primary_10_1056_NEJMoa1200920 crossref_primary_10_18632_oncotarget_9271 crossref_primary_10_1097_PAS_0000000000000445 crossref_primary_10_5858_arpa_2017_0203_OA crossref_primary_10_1111_bjh_15518 crossref_primary_10_1182_asheducation_2017_1_304 crossref_primary_10_1007_s00428_020_02750_7 crossref_primary_10_1016_S2352_3026_20_30291_X crossref_primary_10_1111_bjh_15519 crossref_primary_10_1016_S2352_3026_20_30358_6 crossref_primary_10_1136_jclinpath_2012_201217 crossref_primary_10_1038_s41375_023_01977_y crossref_primary_10_1007_s12308_017_0295_x crossref_primary_10_5045_br_2016_51_2_127 crossref_primary_10_1002_cncr_25756 crossref_primary_10_1111_his_12207 crossref_primary_10_1200_JCO_2015_63_8387 crossref_primary_10_1111_his_13935 crossref_primary_10_3390_diagnostics13193107 crossref_primary_10_1007_s00428_021_03022_8 crossref_primary_10_1016_S0208_5216_13_70056_1 crossref_primary_10_1111_his_15327 crossref_primary_10_1177_2040620714561579 crossref_primary_10_1007_s12185_020_02903_z crossref_primary_10_1093_jnci_djw263 crossref_primary_10_3109_10428194_2014_975700 crossref_primary_10_1080_10428194_2023_2226278 crossref_primary_10_1634_theoncologist_2018_0361 crossref_primary_10_1016_j_jcpa_2021_10_003 crossref_primary_10_1177_107327481201900307 crossref_primary_10_1053_j_semdp_2021_03_006 crossref_primary_10_1182_blood_2022015851 crossref_primary_10_3390_diagnostics14151584 crossref_primary_10_1158_1078_0432_CCR_14_0889 crossref_primary_10_3109_10428194_2012_711828 crossref_primary_10_1093_annonc_mdx223 crossref_primary_10_1002_hon_2160 crossref_primary_10_1016_S0140_6736_16_00739_X crossref_primary_10_1182_blood_2018_03_838136 crossref_primary_10_1016_j_jaap_2016_02_019 crossref_primary_10_1007_s00277_010_1070_6 crossref_primary_10_3389_fonc_2023_1108837 crossref_primary_10_1186_s40164_022_00293_y crossref_primary_10_1016_j_clml_2024_03_010 crossref_primary_10_3233_CBM_182193 crossref_primary_10_3390_hemato5030026 crossref_primary_10_18632_oncotarget_28258 crossref_primary_10_1111_his_12624 crossref_primary_10_3109_10428194_2013_815349 crossref_primary_10_1093_jnen_nlaa006 crossref_primary_10_1111_bjh_15281 crossref_primary_10_1053_j_seminhematol_2018_05_003 crossref_primary_10_1186_s13023_021_01698_4 crossref_primary_10_1002_cncy_22077 crossref_primary_10_1111_bjh_15170 crossref_primary_10_1038_s41375_021_01311_4 crossref_primary_10_1590_1806_9282_64_06_525 crossref_primary_10_1080_17474086_2019_1639501 crossref_primary_10_1182_blood_2011_12_400580 crossref_primary_10_1111_bjh_12046 crossref_primary_10_1093_annonc_mdr450 crossref_primary_10_3109_10428194_2013_815353 crossref_primary_10_1016_j_hemonc_2017_02_003 crossref_primary_10_1007_s12672_018_0336_7 crossref_primary_10_1007_s00259_010_1469_2 crossref_primary_10_1186_1746_1596_8_48 crossref_primary_10_1007_s00277_024_05962_y crossref_primary_10_1002_hon_2188 crossref_primary_10_1111_bjh_13818 |
| Cites_doi | 10.1200/JCO.2006.09.4490 10.1007/s00277-003-0774-2 10.1200/JCO.2005.08.133 10.1111/j.1600-0609.2005.00540.x 10.1038/sj.leu.2403387 10.1182/blood-2004-03-0982 10.1016/j.amjsurg.2003.07.002 10.1016/S1535-6108(03)00028-X 10.1038/sj.leu.2403478 10.1016/j.humpath.2006.11.021 10.1038/sj.bjc.6602795 10.1182/blood-2005-10-4079 10.1111/j.1365-2141.2005.05716.x 10.1182/blood-2004-10-3883 10.1182/blood-2007-06-095331 10.1097/01.pai.0000144557.31747.b9 10.1200/JCO.2005.05.019 10.3324/haematol.11267 10.1172/JCI23409 10.1182/blood-2007-10-117010 |
| ContentType | Journal Article |
| Copyright | Springer-Verlag 2009 |
| Copyright_xml | – notice: Springer-Verlag 2009 |
| CorporateAuthor | for the European MCL Network European MCL Network |
| CorporateAuthor_xml | – name: for the European MCL Network – name: European MCL Network |
| DBID | C6C AAYXX CITATION NPM 5PM |
| DOI | 10.1007/s12308-009-0036-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1865-5785 |
| EndPage | 111 |
| ExternalDocumentID | PMC2725281 19669190 10_1007_s12308_009_0036_x |
| Genre | Journal Article |
| GroupedDBID | -5E -5G -BR -EM -Y2 -~C 06C 06D 0R~ 0VY 203 29K 29~ 2JN 2KG 2VQ 2WC 2~H 30V 4.4 406 408 5GY 67Z 875 8TC 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABMQK ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALFXC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR ANMIH AOCGG AOIJS AUKKA AXYYD B-. BAWUL BDATZ BGNMA C6C CAG COF CS3 CSCUP D-I DDRTE DIK DNIVK DPUIP E3Z EBLON EBS EIOEI EJD EN4 ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GX1 H13 HF~ HMJXF HRMNR HYE HZ~ I0C IJ- IKXTQ IWAJR IXD IZQ J-C J0Z JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O9- O93 O9I O9J OK1 P9S PT4 QOR QOS R89 RLLFE ROL RPM RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 T13 TSG TSK TT1 U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z45 ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION NPM 5PM |
| ID | FETCH-LOGICAL-c423x-dd68d56c9b0b79e0683f2d43a979d953bdc03abc3a788055d3206a7404e70f1c3 |
| IEDL.DBID | C6C |
| ISSN | 1868-9256 |
| IngestDate | Thu Aug 21 14:06:25 EDT 2025 Thu Jan 02 22:04:21 EST 2025 Tue Jul 01 03:32:05 EDT 2025 Thu Apr 24 22:56:53 EDT 2025 Fri Feb 21 02:34:41 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | European MCL Network Ki-67 Consensus guidelines Prognostic marker Mantle cell lymphoma |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c423x-dd68d56c9b0b79e0683f2d43a979d953bdc03abc3a788055d3206a7404e70f1c3 |
| OpenAccessLink | https://doi.org/10.1007/s12308-009-0036-x |
| PMID | 19669190 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2725281 pubmed_primary_19669190 crossref_citationtrail_10_1007_s12308_009_0036_x crossref_primary_10_1007_s12308_009_0036_x springer_journals_10_1007_s12308_009_0036_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20090700 |
| PublicationDateYYYYMMDD | 2009-07-01 |
| PublicationDate_xml | – month: 7 year: 2009 text: 20090700 |
| PublicationDecade | 2000 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany |
| PublicationTitle | Journal of hematopathology |
| PublicationTitleAbbrev | J Hematopathol |
| PublicationTitleAlternate | J Hematop |
| PublicationYear | 2009 |
| Publisher | Springer-Verlag |
| Publisher_xml | – name: Springer-Verlag |
| References | de JongDRosenwaldAChhanabhaiMGaulardPKlapperWLeeASanderBThornsCCampoEMolinaTNortonAHagenbeekAHorningSListerARaemaekersJGascoyneRDSallesGWellerEImmunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker ConsortiumJ Clin Oncol2007258058121732760210.1200/JCO.2006.09.4490 DreylingMLenzGHosterEVan HoofAGisselbrechtCSchmitsRMetznerBTruemperLReiserMSteinhauerHBoironJMBoogaertsMAAldaoudASilingardiVKluin-NelemansHCHasfordJParwareschRUnterhaltMHiddemannWEarly consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood2005105267726841559111210.1182/blood-2004-10-38831:CAS:528:DC%2BD2MXivFGmsbY%3D HosterEDreylingMKlapperWGisselbrechtCVan HoofAKluin-NelemansHCPfreundschuhMReiserMMetznerBEinseleHPeterNJungWWormannBLudwigWDDuhrsenUEimermacherHWandtHHasfordJHiddemannWUnterhaltMA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood20081115585651796251210.1182/blood-2007-06-0953311:CAS:528:DC%2BD1cXns1Cgtw%3D%3D KatzenbergerTPetzoldtCHollerSMaderUKallaJAdamPOttMMMuller-HermelinkHKRosenwaldAOttGThe Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphomaBlood200610734071659759710.1182/blood-2005-10-40791:CAS:528:DC%2BD28Xjs1Oksbw%3D LenzGDreylingMSchiegnitzEForstpointnerRWandtHFreundMHessGTruemperLDiehlVKropffMKnebaMSchmitzNMetznerBPfirrmannMUnterhaltMHiddemannWMyeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma StudyBlood2004104266726741523842010.1182/blood-2004-03-09821:CAS:528:DC%2BD2cXpslKjsL0%3D StantonKJSidnerRAMillerGACummingsOWSchmidtCMHowardTJWiebkeEAAnalysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreasAm J Surg20031864864921459961210.1016/j.amjsurg.2003.07.0021:CAS:528:DC%2BD3sXos1Omtrc%3D SchraderCJanssenDMeusersPBrittingerGSiebmannJUParwareschRTiemannMRepp 86: a new prognostic marker in mantle cell lymphomaEur J Haematol2005754985041631326210.1111/j.1600-0609.2005.00540.x1:CAS:528:DC%2BD2MXhtlelsL%2FM DetermannOHosterEOttGWolframBHLoddenkemperCLeoHMBarthTEUnterhaltMHiddemannWDreylingMKlapperWKi-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupBlood2008111238523871807779110.1182/blood-2007-10-1170101:CAS:528:DC%2BD1cXisVeitb4%3D FernandezVHartmannEOttGCampoERosenwaldAPathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathwaysJ Clin Oncol200523636463691615502110.1200/JCO.2005.05.0191:CAS:528:DC%2BD2MXhtFWntbbK RosenwaldAWrightGWiestnerAChanWCConnorsJMCampoEGascoyneRDGroganTMMuller-HermelinkHKSmelandEBChiorazziMGiltnaneJMHurtEMZhaoHAverettLHenricksonSYangLPowellJWilsonWHJaffeESSimonRKlausnerRDMontserratEBoschFGreinerTCWeisenburgerDDSangerWGDaveBJLynchJCVoseJArmitageJOFisherRIMillerTPLeBlancMOttGKvaloySHolteHDelabieJStaudtLMThe proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaCancer Cell200331851971262041210.1016/S1535-6108(03)00028-X1:CAS:528:DC%2BD3sXhvFyrsrc%3D LenzGDreylingMHiddemannWMantle cell lymphoma: established therapeutic options and future directionsAnn Hematol20048371771466904010.1007/s00277-003-0774-21:STN:280:DC%2BD2c%2Fit1OmsA%3D%3D BottcherSRitgenMBuskeSGeskSKlapperWHosterEHiddemannWUnterhaltMDreylingMSiebertRKnebaMPottCMinimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsHaematologica2008935515591837901010.3324/haematol.11267 BottcherSRitgenMPottCBruggemannMRaffTStilgenbauerSDohnerHDregerPKnebaMComparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantationLeukemia200418163716451534334810.1038/sj.leu.24034781:STN:280:DC%2BD2cvotlKluw%3D%3D SwerdlowSHCampoEHarrisNLJaffeESPileriSASteinHThieleJVardimanJWWHO classification of tumors of the haematopoietic and lymphoid tissues2008LyonIARC ZhangKPrichardJWYoderSDeJLinFUtility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysisHum Pathol2007388788821735066810.1016/j.humpath.2006.11.0211:CAS:528:DC%2BD2sXlsFKgsrw%3D JaffeEHarrisNSteinHVardimanJWPathology and genetics of tumours of haematopoetic and lymphoid tissues2001Lyon, FranceIARC SchraderCJanssenDKlapperWSiebmannJUMeusersPBrittingerGKnebaMTiemannMParwareschRMinichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphomaBr J Cancer2005939399451618952210.1038/sj.bjc.66027951:CAS:528:DC%2BD2MXhtV2kt7vL MessmerBTMessmerDAllenSLKolitzJEKudalkarPCesarDMurphyEJKoduruPFerrariniMZupoSCutronaGDamleRNWasilTRaiKRHellersteinMKChiorazziNIn vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cellsJ Clin Invest2005115755764157116421:CAS:528:DC%2BD2MXit1emt7g%3D SchraderCMeusersPBrittingerGTeymoortashASiebmannJUJanssenDParwareschRTiemannMTopoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcomeLeukemia200418120012061511612110.1038/sj.leu.24033871:CAS:528:DC%2BD2cXkvF2ku78%3D ColemanKEBratDJCotsonisGALawsonDCohenCProliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significanceAppl Immunohistochem Mol Morphol2006141091141654074110.1097/01.pai.0000144557.31747.b91:CAS:528:DC%2BD28XivFCnsLg%3D TiemannMSchraderCKlapperWDreylingMHCampoENortonABergerFKluinPOttGPileriSPedrinisEFellerACMerzHJanssenDHansmannMLKriekenHMollerPSteinHUnterhaltMHiddemannWParwareschRHistopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL NetworkBr J Haematol200513129381617396010.1111/j.1365-2141.2005.05716.x LenzGDreylingMHosterEWormannBDuhrsenUMetznerBEimermacherHNeubauerAWandtHSteinhauerHMartinSHeidemannEAldaoudAParwareschRHasfordJUnterhaltMHiddemannWImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol200523198419921566846710.1200/JCO.2005.08.1331:CAS:528:DC%2BD2MXjt1Cku7g%3D O Determann (36_CR6) 2008; 111 G Lenz (36_CR13) 2005; 23 G Lenz (36_CR14) 2004; 104 BT Messmer (36_CR15) 2005; 115 C Schrader (36_CR19) 2004; 18 T Katzenberger (36_CR11) 2006; 107 M Dreyling (36_CR7) 2005; 105 S Bottcher (36_CR3) 2004; 18 SH Swerdlow (36_CR1) 2008 M Tiemann (36_CR21) 2005; 131 KJ Stanton (36_CR20) 2003; 186 S Bottcher (36_CR2) 2008; 93 G Lenz (36_CR12) 2004; 83 C Schrader (36_CR18) 2005; 75 KE Coleman (36_CR4) 2006; 14 C Schrader (36_CR17) 2005; 93 V Fernandez (36_CR8) 2005; 23 E Hoster (36_CR9) 2008; 111 E Jaffe (36_CR10) 2001 A Rosenwald (36_CR16) 2003; 3 D de Jong (36_CR5) 2007; 25 K Zhang (36_CR22) 2007; 38 18077791 - Blood. 2008 Feb 15;111(4):2385-7 18379010 - Haematologica. 2008 Apr;93(4):551-9 14669040 - Ann Hematol. 2004 Feb;83(2):71-7 16189522 - Br J Cancer. 2005 Oct 17;93(8):939-45 16540741 - Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):109-14 12620412 - Cancer Cell. 2003 Feb;3(2):185-97 16155021 - J Clin Oncol. 2005 Sep 10;23(26):6364-9 16597597 - Blood. 2006 Apr 15;107(8):3407 15591112 - Blood. 2005 Apr 1;105(7):2677-84 15238420 - Blood. 2004 Nov 1;104(9):2667-74 16173960 - Br J Haematol. 2005 Oct;131(1):29-38 17327602 - J Clin Oncol. 2007 Mar 1;25(7):805-12 14599612 - Am J Surg. 2003 Nov;186(5):486-92 15116121 - Leukemia. 2004 Jul;18(7):1200-6 17350668 - Hum Pathol. 2007 Jun;38(6):878-82 17962512 - Blood. 2008 Jan 15;111(2):558-65 16313262 - Eur J Haematol. 2005 Dec;75(6):498-504 15343348 - Leukemia. 2004 Oct;18(10):1637-45 15711642 - J Clin Invest. 2005 Mar;115(3):755-64 15668467 - J Clin Oncol. 2005 Mar 20;23(9):1984-92 |
| References_xml | – reference: TiemannMSchraderCKlapperWDreylingMHCampoENortonABergerFKluinPOttGPileriSPedrinisEFellerACMerzHJanssenDHansmannMLKriekenHMollerPSteinHUnterhaltMHiddemannWParwareschRHistopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL NetworkBr J Haematol200513129381617396010.1111/j.1365-2141.2005.05716.x – reference: DetermannOHosterEOttGWolframBHLoddenkemperCLeoHMBarthTEUnterhaltMHiddemannWDreylingMKlapperWKi-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupBlood2008111238523871807779110.1182/blood-2007-10-1170101:CAS:528:DC%2BD1cXisVeitb4%3D – reference: HosterEDreylingMKlapperWGisselbrechtCVan HoofAKluin-NelemansHCPfreundschuhMReiserMMetznerBEinseleHPeterNJungWWormannBLudwigWDDuhrsenUEimermacherHWandtHHasfordJHiddemannWUnterhaltMA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood20081115585651796251210.1182/blood-2007-06-0953311:CAS:528:DC%2BD1cXns1Cgtw%3D%3D – reference: KatzenbergerTPetzoldtCHollerSMaderUKallaJAdamPOttMMMuller-HermelinkHKRosenwaldAOttGThe Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphomaBlood200610734071659759710.1182/blood-2005-10-40791:CAS:528:DC%2BD28Xjs1Oksbw%3D – reference: BottcherSRitgenMPottCBruggemannMRaffTStilgenbauerSDohnerHDregerPKnebaMComparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantationLeukemia200418163716451534334810.1038/sj.leu.24034781:STN:280:DC%2BD2cvotlKluw%3D%3D – reference: MessmerBTMessmerDAllenSLKolitzJEKudalkarPCesarDMurphyEJKoduruPFerrariniMZupoSCutronaGDamleRNWasilTRaiKRHellersteinMKChiorazziNIn vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cellsJ Clin Invest2005115755764157116421:CAS:528:DC%2BD2MXit1emt7g%3D – reference: RosenwaldAWrightGWiestnerAChanWCConnorsJMCampoEGascoyneRDGroganTMMuller-HermelinkHKSmelandEBChiorazziMGiltnaneJMHurtEMZhaoHAverettLHenricksonSYangLPowellJWilsonWHJaffeESSimonRKlausnerRDMontserratEBoschFGreinerTCWeisenburgerDDSangerWGDaveBJLynchJCVoseJArmitageJOFisherRIMillerTPLeBlancMOttGKvaloySHolteHDelabieJStaudtLMThe proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaCancer Cell200331851971262041210.1016/S1535-6108(03)00028-X1:CAS:528:DC%2BD3sXhvFyrsrc%3D – reference: SchraderCJanssenDMeusersPBrittingerGSiebmannJUParwareschRTiemannMRepp 86: a new prognostic marker in mantle cell lymphomaEur J Haematol2005754985041631326210.1111/j.1600-0609.2005.00540.x1:CAS:528:DC%2BD2MXhtlelsL%2FM – reference: SchraderCMeusersPBrittingerGTeymoortashASiebmannJUJanssenDParwareschRTiemannMTopoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcomeLeukemia200418120012061511612110.1038/sj.leu.24033871:CAS:528:DC%2BD2cXkvF2ku78%3D – reference: LenzGDreylingMSchiegnitzEForstpointnerRWandtHFreundMHessGTruemperLDiehlVKropffMKnebaMSchmitzNMetznerBPfirrmannMUnterhaltMHiddemannWMyeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma StudyBlood2004104266726741523842010.1182/blood-2004-03-09821:CAS:528:DC%2BD2cXpslKjsL0%3D – reference: FernandezVHartmannEOttGCampoERosenwaldAPathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathwaysJ Clin Oncol200523636463691615502110.1200/JCO.2005.05.0191:CAS:528:DC%2BD2MXhtFWntbbK – reference: ZhangKPrichardJWYoderSDeJLinFUtility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysisHum Pathol2007388788821735066810.1016/j.humpath.2006.11.0211:CAS:528:DC%2BD2sXlsFKgsrw%3D – reference: de JongDRosenwaldAChhanabhaiMGaulardPKlapperWLeeASanderBThornsCCampoEMolinaTNortonAHagenbeekAHorningSListerARaemaekersJGascoyneRDSallesGWellerEImmunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker ConsortiumJ Clin Oncol2007258058121732760210.1200/JCO.2006.09.4490 – reference: LenzGDreylingMHosterEWormannBDuhrsenUMetznerBEimermacherHNeubauerAWandtHSteinhauerHMartinSHeidemannEAldaoudAParwareschRHasfordJUnterhaltMHiddemannWImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol200523198419921566846710.1200/JCO.2005.08.1331:CAS:528:DC%2BD2MXjt1Cku7g%3D – reference: DreylingMLenzGHosterEVan HoofAGisselbrechtCSchmitsRMetznerBTruemperLReiserMSteinhauerHBoironJMBoogaertsMAAldaoudASilingardiVKluin-NelemansHCHasfordJParwareschRUnterhaltMHiddemannWEarly consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood2005105267726841559111210.1182/blood-2004-10-38831:CAS:528:DC%2BD2MXivFGmsbY%3D – reference: ColemanKEBratDJCotsonisGALawsonDCohenCProliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significanceAppl Immunohistochem Mol Morphol2006141091141654074110.1097/01.pai.0000144557.31747.b91:CAS:528:DC%2BD28XivFCnsLg%3D – reference: SchraderCJanssenDKlapperWSiebmannJUMeusersPBrittingerGKnebaMTiemannMParwareschRMinichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphomaBr J Cancer2005939399451618952210.1038/sj.bjc.66027951:CAS:528:DC%2BD2MXhtV2kt7vL – reference: BottcherSRitgenMBuskeSGeskSKlapperWHosterEHiddemannWUnterhaltMDreylingMSiebertRKnebaMPottCMinimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsHaematologica2008935515591837901010.3324/haematol.11267 – reference: StantonKJSidnerRAMillerGACummingsOWSchmidtCMHowardTJWiebkeEAAnalysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreasAm J Surg20031864864921459961210.1016/j.amjsurg.2003.07.0021:CAS:528:DC%2BD3sXos1Omtrc%3D – reference: SwerdlowSHCampoEHarrisNLJaffeESPileriSASteinHThieleJVardimanJWWHO classification of tumors of the haematopoietic and lymphoid tissues2008LyonIARC – reference: JaffeEHarrisNSteinHVardimanJWPathology and genetics of tumours of haematopoetic and lymphoid tissues2001Lyon, FranceIARC – reference: LenzGDreylingMHiddemannWMantle cell lymphoma: established therapeutic options and future directionsAnn Hematol20048371771466904010.1007/s00277-003-0774-21:STN:280:DC%2BD2c%2Fit1OmsA%3D%3D – volume: 25 start-page: 805 year: 2007 ident: 36_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.4490 – volume: 83 start-page: 71 year: 2004 ident: 36_CR12 publication-title: Ann Hematol doi: 10.1007/s00277-003-0774-2 – volume: 23 start-page: 1984 year: 2005 ident: 36_CR13 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.08.133 – volume: 75 start-page: 498 year: 2005 ident: 36_CR18 publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2005.00540.x – volume: 18 start-page: 1200 year: 2004 ident: 36_CR19 publication-title: Leukemia doi: 10.1038/sj.leu.2403387 – volume: 104 start-page: 2667 year: 2004 ident: 36_CR14 publication-title: Blood doi: 10.1182/blood-2004-03-0982 – volume-title: WHO classification of tumors of the haematopoietic and lymphoid tissues year: 2008 ident: 36_CR1 – volume: 186 start-page: 486 year: 2003 ident: 36_CR20 publication-title: Am J Surg doi: 10.1016/j.amjsurg.2003.07.002 – volume: 3 start-page: 185 year: 2003 ident: 36_CR16 publication-title: Cancer Cell doi: 10.1016/S1535-6108(03)00028-X – volume: 18 start-page: 1637 year: 2004 ident: 36_CR3 publication-title: Leukemia doi: 10.1038/sj.leu.2403478 – volume-title: Pathology and genetics of tumours of haematopoetic and lymphoid tissues year: 2001 ident: 36_CR10 – volume: 38 start-page: 878 year: 2007 ident: 36_CR22 publication-title: Hum Pathol doi: 10.1016/j.humpath.2006.11.021 – volume: 93 start-page: 939 year: 2005 ident: 36_CR17 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602795 – volume: 107 start-page: 3407 year: 2006 ident: 36_CR11 publication-title: Blood doi: 10.1182/blood-2005-10-4079 – volume: 131 start-page: 29 year: 2005 ident: 36_CR21 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2005.05716.x – volume: 105 start-page: 2677 year: 2005 ident: 36_CR7 publication-title: Blood doi: 10.1182/blood-2004-10-3883 – volume: 111 start-page: 558 year: 2008 ident: 36_CR9 publication-title: Blood doi: 10.1182/blood-2007-06-095331 – volume: 14 start-page: 109 year: 2006 ident: 36_CR4 publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/01.pai.0000144557.31747.b9 – volume: 23 start-page: 6364 year: 2005 ident: 36_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.019 – volume: 93 start-page: 551 year: 2008 ident: 36_CR2 publication-title: Haematologica doi: 10.3324/haematol.11267 – volume: 115 start-page: 755 year: 2005 ident: 36_CR15 publication-title: J Clin Invest doi: 10.1172/JCI23409 – volume: 111 start-page: 2385 year: 2008 ident: 36_CR6 publication-title: Blood doi: 10.1182/blood-2007-10-117010 – reference: 16173960 - Br J Haematol. 2005 Oct;131(1):29-38 – reference: 15116121 - Leukemia. 2004 Jul;18(7):1200-6 – reference: 15711642 - J Clin Invest. 2005 Mar;115(3):755-64 – reference: 17327602 - J Clin Oncol. 2007 Mar 1;25(7):805-12 – reference: 18379010 - Haematologica. 2008 Apr;93(4):551-9 – reference: 15238420 - Blood. 2004 Nov 1;104(9):2667-74 – reference: 12620412 - Cancer Cell. 2003 Feb;3(2):185-97 – reference: 16155021 - J Clin Oncol. 2005 Sep 10;23(26):6364-9 – reference: 14669040 - Ann Hematol. 2004 Feb;83(2):71-7 – reference: 15591112 - Blood. 2005 Apr 1;105(7):2677-84 – reference: 15343348 - Leukemia. 2004 Oct;18(10):1637-45 – reference: 15668467 - J Clin Oncol. 2005 Mar 20;23(9):1984-92 – reference: 16597597 - Blood. 2006 Apr 15;107(8):3407 – reference: 16189522 - Br J Cancer. 2005 Oct 17;93(8):939-45 – reference: 16313262 - Eur J Haematol. 2005 Dec;75(6):498-504 – reference: 18077791 - Blood. 2008 Feb 15;111(4):2385-7 – reference: 16540741 - Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):109-14 – reference: 17962512 - Blood. 2008 Jan 15;111(2):558-65 – reference: 14599612 - Am J Surg. 2003 Nov;186(5):486-92 – reference: 17350668 - Hum Pathol. 2007 Jun;38(6):878-82 |
| SSID | ssj0064493 |
| Score | 2.195109 |
| Snippet | Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B cell non-Hodgkin lymphoma; however, there are some indolent cases... |
| SourceID | pubmedcentral pubmed crossref springer |
| SourceType | Open Access Repository Index Database Enrichment Source Publisher |
| StartPage | 103 |
| SubjectTerms | Hematology Medicine Medicine & Public Health Original Original Article Pathology |
| Title | Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network |
| URI | https://link.springer.com/article/10.1007/s12308-009-0036-x https://www.ncbi.nlm.nih.gov/pubmed/19669190 https://pubmed.ncbi.nlm.nih.gov/PMC2725281 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9swFBajhdGXslvbrFvRw55WRBXJsqzHEHphXcIeGsiejCQrbSBVRt1A91L2I_YL-0t6ji8pCVuhL7KwZSP8yTqfzjn-RMgXAZhL4TjjzjiWeNdlJmjFMqsyMLFBS4f-jsEwPRsl38Zq3IhF478wa_H7oxJmVgzQowsftXOBLm4qmHdxMPfTfjvpglWv9HVR_J0ZMONtAPNfj1gxQUu7s54TuRYYrezNyRuy3RBF2quRfUtehfiOvB40ofD35P58ylJNbUktxSSrOEfFZXqN6TY3dBqhFmEcUPTM09lvAG1-bR_-_PWYPh3LRUkvFyhxhWnvdD6hQAQpbk9cudmhFsOsPd167Omg_50O67zxD2R0cnzRP2PNZgrMA2O6Y0WRZoVKvXHcaRN4msmJKBJpjTaFUdIVnkvrvLSwKOZKFVLw1OqEJ0HzSdfLHbIR5zHsEZpJD0Yt8ZkF_gG3ODjw0DVW6KwAvtkhvH2_uW-UxnHDi1n-pJGMkOQACWqTpvldh3xd3vKrltl4rvFujdVTU1i0GaA2HaJXUFw2QBHt1StxelWJaQstlMigz4ct3nnzFZf_78HHF7XeJ1t1DAqTfD-RjdubRfgMVObWHZDN3unP8-ODajBDeTruQjn8MYByJHqPYCvwxw |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NTxsxELUqkEoviBZaQin1gVMrS469u7aPKCJKS5ITkbitbK_TRgoOYokEF8SP6C_sL-nMfiQKaitxWmvXXll-3p3nmfEzIacCMJfCccadcSzxrstMUCnTNtVgYoOSDv0do3E2mCTfr9KrZh932Wa7tyHJ6k-93uwGbFmzypmPKrpAHLcxyogrrok4a3-_YN8rpV2UgWcGDHobyvzbKzaM0coCPc-OfBYirSxPf4_sNpSRntUYvyWvQnxHXo-aoPg-ebyYsUxRW1JLMd0qLlB7mV5j4s0tnUUoRZgRFH30dP4A8C2u7e-nXx4TqWO5LOmPJYpdYQI8XUwpUEKKBxVXDncoxTBvb7e-ezrqDem4ziA_IJP--WVvwJpjFZiH8bpnRZHpIs28cdwpE3im5VQUibRGmcKk0hWeS-u8tLA85mlaSMEzqxKeBMWnXS_fk624iOGQUC09mLfEawtMBJo4uPDQNVYoXQDz7BDejm_uG81xPPpinq_VkhGSHCBBldIsv--QL6smN7Xgxv8qf6ixWleF5ZsBktMhagPFVQWU0958Emc_K1ltoUQqNPT5a4t33nzP5b97cPSi2p_JzuByNMyH38YXH8mbOjKFqb_HZOvudhk-AcG5cyfVhP4DT-DzXQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LTxsxELYqKqFeqj5om0KLDz1RWTjr3bV9RKERFBJxAInbyq9ApMRBbCLBBfEj-gv7S5jZR6KgtlJPa-3Orqwd787nmc-fCfmWgM9FYjnjVluWOttlOsiMKZMpCLFBCov5jsEwP7pIf15ml80-p2XLdm9LkvWaBlRpivP9Gz_aXy18A-SsWJXYR0VdAJEvUaoLOX29vNf-iiHWV6q7KAnPNAT3tqz5p0esBaZlNHrOlHxWLq2iUP8Ned3AR3pQ-_steRHiO7I5aArk78nDyZjlkpqSGorUqzhDHWY6RRLOLR1HaEUYHRTz9XRyD66cTc3vx18OSdWxXJT0aoHCV0iGp7MRBXhIcdPiKvkOrRgm7ek2j08HvVM6rNnkW-Si_-O8d8SaLRaYAxx1x7zPlc9ypy23UgeeKzFKfCqMltrrTFjvuDDWCQNTZZ5lXiQ8NzLlaZB81HXiA9mIsxg-EaqEg1CXOmUAlcAtFg48dLVJpPKAQjuEt--3cI3-OG6DMSlWysnokgJcgoqleXHXIXvLW25q8Y1_GX-sfbUyhamcBsDTIXLNi0sDlNZevxLH15XEdiKTLFHQ5--tv4vm2y7_3oPP_2W9SzbPDvvF6fHwZJu8qotUyALeIRvz20X4Alhnbr9W4_kJGzr3jA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ki-67+as+a+prognostic+marker+in+mantle+cell+lymphoma%E2%80%94consensus+guidelines+of+the+pathology+panel+of+the+European+MCL+Network&rft.jtitle=Journal+of+hematopathology&rft.au=Klapper%2C+Wolfram&rft.au=Hoster%2C+Eva&rft.au=Determann%2C+Olaf&rft.au=Oschlies%2C+Ilske&rft.date=2009-07-01&rft.pub=Springer-Verlag&rft.issn=1868-9256&rft.eissn=1865-5785&rft.volume=2&rft.issue=2&rft.spage=103&rft.epage=111&rft_id=info:doi/10.1007%2Fs12308-009-0036-x&rft_id=info%3Apmid%2F19669190&rft.externalDocID=PMC2725281 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1868-9256&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1868-9256&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1868-9256&client=summon |